Nasus Pharma Ltd (NSRX)

$6.85 -0.14 (-2.00%)
Market Cap 66.40M
Revenue (ttm) 0.00
Net Income (ttm) -1.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 965
Avg Vol 16,536
Day's Range N/A - N/A
Shares Out 9.06M
Stochastic %K 40%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

Nasus Pharma Ltd. operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions. The company offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats. The company's products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 972 3 573 6632
Address:
Yigal Alon 65, Tel Aviv-Yafo, Israel
Latest News on NSRX
Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Nov 20, 2025, 8:15 AM EST - 14 days ago

Nasus Pharma Strengthens Leadership Team, Appointing Eyal Rubin as Executive Vice President and Chief Financial Officer

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Nov 18, 2025, 8:00 AM EST - 16 days ago

Nasus Pharma Announces Initiation of Phase 2 Clinical Study of NS002 with First Participant Dosed

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nov 6, 2025, 8:00 AM EST - 4 weeks ago

Nasus Pharma Announces Approval from Health Canada to Initiate Planned Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Oct 8, 2025, 8:04 AM EDT - 2 months ago

Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:00 AM EDT - 3 months ago

Nasus Pharma Announces Upcoming Presentation at H.C. Wainwright 27th Annual Global Investment Conference

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

Aug 26, 2025, 8:00 AM EDT - 3 months ago

Nasus Pharma Marks NYSE American Listing with Bell Ringing Ceremony

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

Aug 16, 2025, 12:25 AM EDT - 3 months ago

U.S. IPO Weekly Recap: Bullish And Miami International Complete The Last Major IPOs Of The Summer

BLSH BUUU KLAR MAGH MIAX NUTR PPCB

Nasus Pharma Announces Closing of Initial Public Offering

Aug 14, 2025, 4:05 PM EDT - 4 months ago

Nasus Pharma Announces Closing of Initial Public Offering

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Aug 13, 2025, 7:30 AM EDT - 4 months ago

Nasus Pharma Announces Pricing of $10 Million Initial Public Offering

Nasus Pharma IPO Shows Promise But Risks Remain

Jul 16, 2025, 11:14 AM EDT - 5 months ago

Nasus Pharma IPO Shows Promise But Risks Remain

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Jul 9, 2025, 5:40 PM EDT - 5 months ago

Israeli severe allergy biotech Nasus Pharma files and sets terms for an $11 million US IPO

Nasus Pharma IPO Registration Document (F-1)

Jul 9, 2025, 3:59 PM EDT - 5 months ago

Nasus Pharma IPO Registration Document (F-1)